Abivax SA American Depositary Shares (ABVX)
Stock · NASDAQ · Health Care
$113.35as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$120.15
Industry
Biotechnology: Pharmaceutical Preparations
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. T…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 80
- Website
- www.abivax.com/
Fundamentals
- 1-day range
- $111.72$115.17
- Market cap
- $10.74B
- P/E (trailing)
- —
- P/E (forward)
- -36.03
- EPS (trailing)
- $-5.31
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 2.02M
52-week range
$60.45$139
Next earnings: September 21, 2026confirmed
Forecasts
11 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$187
+65.0%
Median
$170
+50.0%
Low
$142
+25.3%
Abivax SA American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ABVXAbivax SA American Depositary Shares$113.41▼ 0.78%Market cap $10.74BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$199.01▼ 3.52%Market cap $10.86BP/E —$112.9$260.19
- SMMTSummit Therapeutics Inc. Common Stock$13.71▼ 4.33%Market cap $10.41BP/E —$12.07$29.23
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$534.12▼ 1.76%Market cap $11.14BP/E —$393.61$615
- CYTKCytokinetics Incorporated Common Stock$72.17▼ 7.36%Market cap $9.51BP/E —$35.22$88.31
- ELANElanco Animal Health Incorporated Common Stock$24.12▼ 1.51%Market cap $12.85BP/E —$17.11$27.98
- SYRESpyre Therapeutics Inc. Common Stock$90.4▼ 3.43%Market cap $8.35BP/E —$14.51$110.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABVX Abivax SA American Depositary Shares | $10.74B | — | $113.41 | ▼ 0.78% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.86B | — | $199.01 | ▼ 3.52% | $112.9$260.19 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.41B | — | $13.71 | ▼ 4.33% | $12.07$29.23 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.14B | — | $534.12 | ▼ 1.76% | $393.61$615 |
| CYTK Cytokinetics Incorporated Common Stock | $9.51B | — | $72.17 | ▼ 7.36% | $35.22$88.31 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.85B | — | $24.12 | ▼ 1.51% | $17.11$27.98 |
| SYRE Spyre Therapeutics Inc. Common Stock | $8.35B | — | $90.4 | ▼ 3.43% | $14.51$110.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 8/27/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 8/18/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 8/12/2026
- ABIVAX (NASDAQ:ABVX) Flashes Strong Technical Rating and Breakout SetupChartMill · 8/11/2026
- HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; BuySeekingAlpha · 8/7/2026
- Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast CancerYahoo · 8/4/2026
- AbbVie Q2 Earnings Call HighlightsYahoo · 7/31/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 52.15M
- Total value held
- $5.59B
- Institutional holders
- 249
Top holders this quarter
- Unknown6.48M
- Unknown4.55M
- Unknown3.47M
- Unknown1.70M
- Unknown1.50M
- Unknown1.46M
- Unknown1.44M
- Unknown1.34M
- Unknown1.32M
- Unknown1.29M
See the full, filterable feed with live charts on the MarketWall dashboard.